The US president has launched a popular attack on pharmaceutical companies, but analysts question whether the prices will be affordable for many people.
Published on February 6, 2026
President of the United States Donald Trump has launched a new website that it says will lower the cost of prescription drugs, which have long stood for their skyrocketing prices in the US compared to similar products around the world.
At an event at the White House on Thursday, Trump announced the launch of a new website called TrumpRx, which allows consumers to buy discount drugs directly from pharma companies.
Recommended stories
3 List of itemsEnd of list
“People will save a lot of money and be healthier,” Trump said, adding that some of the world’s biggest drugmakers have agreed to lower prices under “most favored nation” deals in exchange for avoiding U.S. tariffs.
The website is launching with savings on more than 40 popular drugs, the White House said.
Users can search the site for the drug they want, then print a coupon and present it to a pharmacy to purchase at a discount.
The Trump administration has taken the initiative as a public attack on powerful pharmaceutical companies amid growing discontent over the state of the economy.
A group of 16 drug companies have agreed to concessions in the deal, under which they will offer lower prices for certain drugs to US consumers through government programs such as Medicaid and TrumpRx.
The TrumpRx site, which promises “the world’s lowest prices on prescription drugs,” showcases more than 40 drugs, including weight-loss drugs like Ozempic and Wegovi, and calls the effort “the most effective prescription price reset in our nation’s history.”
“Thanks to President Trump, the days of Big Pharma price gouging are over,” the website says.
But analysts Questioned The effort will affect US drug prices or shock the pharmaceutical industry.
“There’s a real question about the value of this for people with insurance,” Juliet Cubansky, deputy director of Medicare policy at the health policy organization KFF, told Reuters.
“In some cases, we’re seeing out-of-pocket costs that are still relatively unaffordable for many people,” Cubansky said.
TrumpRX is representative of the US President’s personal policy-making style, looking to cut corners Individual deals Advancing one’s own priorities rather than using traditional regulatory and legislative channels.
A previous analysis by KFF said details of most favored nation agreements with firms “remain confidential, meaning that very little is publicly known about exactly what has been agreed”.
Pharmaceutical companies, along with watchdog groups, are a powerful force in American politics Unlock the secrets Report that pharmaceutical manufacturers will spend a record-high $187m on lobbying activities in 2025.